EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2016-864 10.17179/excli2016-864 Doc870 Editorial material Pathophysiology of cholestatic liver disease and its relevance for in vitro tests of hepatotoxicity Stöber Regina * 1 Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany *To whom correspondence should be addressed: Regina Stöber, Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany, E-mail: stoeber@ifado.de 23 12 2016 2016 15 870 871 12 12 2016 22 12 2016 Copyright © 2016 Stöber 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from http://www.excli.de/vol15/Stoeber_23122016_proof.pdf


Recently, Peter Jansen from the Department of Gastroenterology and Hepatology and colleagues published a comprehensive review about the mechanisms leading to cholestatic liver disease (Jansen et al., 2016[6]). The authors describe the morphological changes at different topological domains of the biliary tree: while large bile ducts respond by enlargement of ductular diameter to maximize their volume, intralobular bile ducts respond by branching and surface corrugation to optimize their capacity to reabsorb bile salts (Vartak et al., 2016[13]). A key mechanism in cholestatic liver disease is that the bile canaliculi in liver lobules become leaky, and toxic bile can get into contact with parenchymal cells leading to cytotoxicity and necrosis, a phenomenon also named bile infarct.

For toxicologists the perhaps most important lesson learned from this review is that cholestatic liver disease may have an ascending and a descending pathophysiology. For example primary sclerosing cholangitis and primary biliary cholangitis begins with early lesions 'downstream' in bile ducts which leads to bile salt-mediated injury 'upstream' in liver parenchyma. In contrast, most forms of drug induced cholestasis have a descending pathophysiology, where damage of hepatocytes represents the initial key event.

Considering this classification it may be justified that in vitro systems to identify hepatotoxic compounds focus on hepatocytes (Miszczuk et al., 2015[7]; Tolosa et al., 2015[12]; Björnsson, 2015[2]; Stöber, 2015[10][11]). Currently, large research programs focus on hepatocyte in vitro systems, either using functional assays (Godoy et al., 2013[4]; Reif et al., 2016[8]) or genome wide expression analysis (Schaap et al., 2015[9]; Benet et al., 2014[1]; Grinberg et al., 2014[5]).

However, it should be taken into account that also toxic cholestasis may in rare cases have an ascending pathophysiology. For example, 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) primarily causes damage to bile ducts, while parenchymal damage occurs as a secondary event (Fickert et al., 2007[3]).

Therefore, insufficient sensitivity in currently performed in vitro screens for hepatotoxicity may be a consequence of neglecting compounds acting by an ascending pathophysiology, where cholangiocytes and not hepatocytes represent primary targets.

Benet M Moya M Donato MT Lahoz A Hervás D Guzmán C A simple transcriptomic signature able to predict drug-induced hepatic steatosis Arch Toxicol 2014 88 967 982 Björnsson ES Drug-induced liver injury: an overview over the most critical compounds Arch Toxicol 2015 89 327 334 Fickert P Stöger U Fuchsbichler A Moustafa T Marschall HU Weiglein AH A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis Am J Pathol 2007 171 525 536 Godoy P Hewitt NJ Albrecht U Andersen ME Ansari N Bhattacharya S Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Arch Toxicol 2013 87 1315 1530 Grinberg M Stöber RM Edlund K Rempel E Godoy P Reif R Toxicogenomics directory of chemically exposed human hepatocytes Arch Toxicol 2014 88 2261 2287 Jansen PL Ghallab A Vartak N Reif R Schaap FG Hampe J The ascending pathophysiology of cholestatic liver disease Hepatology 16 Dec 2016 Epub ahead of print 10.1002/hep.28965. Available from: http://dx.doi.org/10.1002/hep.28965 Miszczuk GS Barosso IR Zucchetti AE Boaglio AC Pellegrino JM Sánchez Pozzi EJ Sandwich-cultured rat hepatocytes as an in vitro model to study canalicular transport alterations in cholestasis Arch Toxicol 2015 89 979 990 Reif R Ghallab A Beattie L Günther G Kuepfer L Kaye PM In vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice Arch Toxicol 20 Dec 2016 Epub ahead of print 10.1007/s00204-016-1906-5. Available from: http://dx.doi.org/10.1007/s00204-016-1906-5 Schaap MM Wackers PF Zwart EP Huijskens I Jonker MJ Hendriks G A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens Arch Toxicol 2015 89 2413 2427 Stoeber R Drug-induced mitochondrial impairment in liver cells EXCLI J 2015 14 1297 1299 Stoeber R Transcriptomic signature for drug-induced steatosis EXCLI J 2015 14 1259 1260 Tolosa L Gómez-Lechón MJ Donato MT High-content screening technology for studying drug-induced hepatotoxicity in cell models Arch Toxicol 2015 89 1007 1022 Vartak N Damle-Vartak A Richter B Dirsch O Dahmen U Hammad S Cholestasis-induced adaptive remodeling of interlobular bile ducts Hepatology 2016 63 951 964